Roche says it will appeal against NICE no for Tarceva
This article was originally published in Scrip
Executive Summary
Roche says it is going to appeal against draft guidance from NICE, the health technology appraisal institute for England and Wales, which turns down the company's Tarceva (erlotinib) as a maintenance treatment for some NHS patients with advanced non-small cell lung cancer (NSCLC). The institute said it had too many doubts about the clinical-effectiveness of the drug in this setting.
You may also be interested in...
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.
Germany Courts Clinical Trials With Regulator Reshuffle & New Federal Ethics Committee
Plans to rejig two regulators’ roles and streamline the ethics committee system have drawn some criticism.